Analysis of somatic mutations and transcriptomes of pre-treatment melanoma patients’ biopsies with PD-1 blockade (pembrolizumab and nivolumab) identified pro-angiogenic factors associated with resistance to ICIs in the non-responding patients, compared to responding pre-treatment tumours [175]. This evidence concerns the gene PDCD1 and melanoma.